Phio Pharmaceuticals to Discuss 'Nobel Prize Winning Science' for Skin Cancer Treatment

Phio's CEO and Chief Medical Officer to host fireside chat with Force Family Office on April 15, 2026

Apr. 13, 2026 at 3:06pm

Got story updates? Submit your updates here. ›

A translucent, ghostly X-ray image revealing the internal structure of a human skin cell, glowing against a dark background to conceptually represent the innovative science behind Phio Pharmaceuticals' INTASYL technology and its potential to treat skin cancer.Phio Pharmaceuticals' novel INTASYL technology aims to harness the power of gene silencing to develop new treatments for skin cancer.King of Prussia Today

Phio Pharmaceuticals, a clinical-stage siRNA biopharmaceutical company, announced it will host a fireside chat with Force Family Office on April 15, 2026. The event will feature Phio's CEO Robert Bitterman, Chairman of the Board, and Dr. R. Todd Plott, Chief Medical Officer of Epiphany Dermatology, who will provide insights on Phio's INTASYL compound PH-762 that silences the PD-1 gene implicated in various forms of skin cancer.

Why it matters

Phio's INTASYL technology represents a differentiated approach to immuno-oncology, potentially offering a non-surgical treatment option for skin cancers like cutaneous squamous cell carcinoma, melanoma, and Merkel cell carcinoma. The fireside chat will provide investors and analysts an opportunity to learn more about Phio's promising pipeline and clinical development progress.

The details

Phio's lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in a Phase 1b trial. The company has reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. Phio has also reported a pathological response rate in cutaneous squamous cell carcinoma across all dosing cohorts of approximately 65%, including an 85% pathological response in the highest-dose cohort.

  • The fireside chat will take place on Wednesday, April 15, 2026 at 12 PM EDT.
  • Phio has indicated that FDA engagement regarding next-stage clinical development for PH-762 is targeted for the second quarter of 2026.
  • Phio has reported cash and cash equivalents projected to sustain operations into the first half of 2027.

The players

Robert Bitterman

CEO and Chairman of the Board, Phio Pharmaceuticals.

R. Todd Plott, M.D.

Chief Medical Officer, Epiphany Dermatology and former consultant to the FDA.

Steven Saltzstein

CEO, Force Family Office.

Phio Pharmaceuticals Corp.

A clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics.

Epiphany Dermatology

A dermatology practice that Dr. Plott is the Chief Medical Officer of.

Got photos? Submit your photos here. ›

What they’re saying

“We are excited to hold this fireside chat with Force Family Office. Dr. Plott will discuss why the INTASYL siRNA program represents a differentiated approach to immuno-oncology.”

— Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals

What’s next

Phio has indicated that FDA engagement regarding next-stage clinical development for PH-762 is targeted for the second quarter of 2026.

The takeaway

Phio's INTASYL technology offers a promising non-surgical treatment approach for various skin cancers, with the potential to leverage 'Nobel Prize winning science' to enhance the body's immune response against tumors. The upcoming fireside chat will provide investors and analysts a deeper look into Phio's clinical progress and future development plans.